Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice (Q34530216)

2 August 2017

1 reference

title

Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice (English)

1 reference

2 August 2017

Alan J Garber

1

1 reference

2 August 2017

1 January 2002

1 reference

Diabetes, Obesity and Metabolism

2 August 2017

1 reference

2 August 2017

4 Suppl 1

1 reference

2 August 2017

S5-12

1 reference

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association

2 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Molecular bases of the acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Evaluating novel cardiovascular risk factors: can we better predict heart attacks?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Acoustic waveform inversion with application to seasonal snow covers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1462-8902.2001.00038.X

10.1046/J.1462-8902.2001.00038.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11843949